About Medtronic plc.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Medtronic plc. (MDT) is a Healthcare company in the Medical Devices industry with a market capitalisation of $116.4B. The stock trades at 22.40x trailing earnings and yields 3.17%.
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $116.4B
- P/E ratio
- 22.40
- Forward P/E
- 14.21
- EPS (TTM)
- $4.06
- Revenue (TTM)
- $37.5B
- Free cash flow
- $5.4B
- Profit margin
- 13.9%
- Dividend yield
- 3.17%
- Beta
- 0.57
- Shares outstanding
- 1.3B
Financial health: Strong8.3/10
6 strengths, 0 concerns. No red flags against these benchmarks.
- Current ratio: 2.13 (Strong, benchmark > 1.5) — Short-term assets cover 2.13x short-term liabilities, against Graham's 1.5x floor. It has deteriorated over the last 4 years.
- Return on equity: 10.7% (Watch, benchmark > 15%) — Earns 10.7% on shareholder equity, short of the > 15% mark.
- Gross margin: 65.3% (Strong, benchmark > 40%) — Keeps 65.3% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 13.9% (Strong, benchmark > 10%) — Turns 13.9% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $5.4B (Strong, benchmark positive) — Generated $5.4B of free cash flow after capital spending. It has improved over the last 4 years.
- Revenue growth: 13.7% (Strong, benchmark > 10%) — Revenue changed 13.7% year on year, comfortably past the > 10% mark.
- Earnings growth: 40.7% (Strong, benchmark > 10%) — Earnings changed 40.7% year on year, comfortably past the > 10% mark.
- PEG ratio: 1.64 (Watch, benchmark < 1) — At 1.64, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 70.2% (Watch, benchmark < 60%) — Pays out 70.2% of earnings as dividends — above the level usually considered sustainable.